metricas
covid
Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Effect of antihypertensive treatment on the quality of life of patients with chr...
Journal Information
Vol. 75. Issue 3.
Pages 155-161 (May - June 2024)
Share
Share
Download PDF
More article options
Visits
14
Vol. 75. Issue 3.
Pages 155-161 (May - June 2024)
Original article
Effect of antihypertensive treatment on the quality of life of patients with chronic rhinosinusitis with nasal polyps
Efecto del tratamiento antihipertensivo en la calidad de vida de los pacientes con rinosinusitis crónica con pólipos nasales
Visits
14
Juan Maza-Solanoa,
Corresponding author
, Carmen Palma-Martíneza, Daniel Martín-Jiméneza, Serafín Sánchez-Gómeza, Ramón Moreno-Lunaa, Christian Calvo-Henriquezb, Hugo Galera-Ruiza
a Servicio de Otorrinolaringología, Hospital Universitario Virgen de la Macarena, Sevilla, Spain
b Servicio de Otorrinolaringología, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Distribution of demographic and medical variables.
Table 2. Distribution of endoscopic variables and quality of life before and after anti-HTA treatment initiation.
Table 3. Pearson correlation test between quality-of-life variables.
Show moreShow less
Abstract
Aim

Nasal polyposis (CRSwNP) shares type 2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post-surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP.

Materials and methods

Retrospective study of 43 patients with CRSwNP and ah with at least 1year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT-22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment.

Results

The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1=27.9% and F2=6.97%). A significant reduction in polypoid size, SNOT22 (16.4±19.6 points), and VAS scales (p<.05) was obtained.

Conclusions

polypoid size, and reduce the risk of postoperative recurrence.

Keywords:
Nasal polyposis
Periostin
Arterial hypertension
SNOT22
Quality of life
Resumen
Objetivo

La poliposis nasal (RSCcPN) comparte con el asma, la alergia o la hipertensión arterial (HTA) biomarcadores de inflamación tipo 2 entre los que se encuentra la periostina, un marcador predictor de severidad y recurrencia postquirúrgica de la poliposis. Los antihipertensivos han demostrado disminuir la expresión de periostina. Nos planteamos evaluar el efecto de los antihipertensivos en la calidad de vida de los pacientes con RSCcPN.

Materiales y métodos

Estudio retrospectivo de 43 pacientes con RSCcPN y HTA con al menos 1 año de seguimiento y tratamiento antihipertensivo, prescrito posteriormente al diagnóstico de la RSCcPN. Se analizaron los fenotipos (F1: RSCcPN aislada; F2: RSCcPN con asma y/o EREA) y los aspectos relacionados con la calidad de vida (SNOT-22), la severidad clínica (EVA), el tamaño polipoideo (NPS), las exacerbaciones y las necesidades quirúrgicas posteriores a la instauración del tratamiento antihipertensivo.

Resultados

El fenotipo predominante fue el F1 (62,8%). El número de exacerbaciones fue del 19,2% para F1, frente al 31,3% para F2. El 34,8% fueron operados posteriormente al inicio del tratamiento antihipertensivo (F1=27,9% y F2=6,97%). Se obtuvo una reducción significativa del tamaño polipoideo, del SNOT22 (16,4±19,6 puntos), y de las escalas EVA (p<0,05).

Conclusiones

Los antihipertensivos administrados en pacientes con RSCcPN e HTA comórbida mejoran la calidad de vida, reducen el tamaño polipoideo y reducen el riesgo de recurrencia postquirúrgica.

Palabras clave:
Poliposis nasal
Periostina
Hipertensión arterial
SNOT22
Calidad de vida

Article

These are the options to access the full texts of the publication Acta Otorrinolaringológica Española
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Acta Otorrinolaringológica Española

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos